Tandem Diabetes Care, Inc.
NASDAQ:TNDMMedical - Devices
+$0.24 today
- Market cap
- $1.19B
- Beta
- 1.57
- P/E (TTM)
- -11.3
- EPS (TTM)
- -$1.38
Volume 2.35M
Average 2.43M
TNDM Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Tandem Diabetes Care, Inc.NASDAQ: TNDM
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $15.66M fell 38.6% year over year, behind the -21.3% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 22.1% from the prior quarter. Over 3 fiscal years it compounded at +2.8% a year.
Context
- Stock-based compensation amounted to 9.1% of revenue in FY2025, down 1.7 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -38.6% toward the trailing-twelve-month pace of -21.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 92.38M USD
- Year-over-year change
- -8.9%
- 4-year CAGR
- +11.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 92.38M | -8.9% |
| FY2024 | 2024-12-31 | 101.38M | +15.1% |
| FY2023 | 2023-12-31 | 88.08M | +3.7% |
| FY2022 | 2022-12-31 | 84.92M | +39.8% |
| FY2021 | 2021-12-31 | 60.75M | — |
Stock-Based Compensation vs competitors
How TNDM compares with its peers on the latest reported figures
- TNDM's LTM Mar 2026 stock-based compensation of $82.55M is the 2nd largest of the 8 companies compared; the peer median is $18.99M.
- Its year-over-year change of -21.3% is the 5th highest of 7, against a peer median of +6.0%.
- Stock-based compensation amounts to 8.0% of revenue for TNDM, versus a peer median of 3.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $162.4M | -2.3% | +8.1% | 3.3% | |
| LTM Mar 2026 | $82.55M | -21.3% | +2.8% | 8.0% | |
| LTM Jun 2026 | $77.9M | +22.1% | +15.3% | 2.6% | |
MMEDMiniMed Group, Inc. Common Stock | LTM Jul 2026 | $47M | — | +9.5% | 1.5% |
| LTM Mar 2026 | $18.99M | +142.5% | +39.0% | 17.2% | |
| LTM Mar 2026 | $14.49M | -36.6% | — | 4.0% | |
| LTM Mar 2026 | $10.59M | +14.3% | +5.6% | 26.0% | |
| LTM Mar 2026 | $7.81M | -26.4% | +28.7% | — | |
MMEDVMiniMed Group, Inc. | — | — | — | — | — |
| Peer median (excluding TNDM) | $18.99M | +6.0% | +12.4% | 3.6% | |
Competitors are the stored peer set for TNDM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 15.57M | (94.59M) | (222.61M) | (96.03M) | (204.71M) |
| Depreciation & Amortization | 13.85M | 14.33M | 15.72M | 16.61M | 13.84M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 60.75M | 84.92M | 88.08M | 101.38M | 92.38M |
| Change in Working Capital | 14.37M | (4.65M) | (17.69M) | (11.78M) | (23.04M) |
| Accounts Receivables | (30.98M) | (7.83M) | 4.28M | (20.8M) | (56.81M) |
| Inventory | (4.95M) | (42.45M) | (46.05M) | 5.81M | 24.82M |
| Accounts Payables | 10.28M | 24.49M | (4.86M) | (2.39M) | 2.23M |
| Other Working Capital | 40.03M | 21.14M | 28.96M | 5.6M | 6.73M |
| Other Non-Cash Items | 6.82M | 50.46M | 104.7M | 14.04M | 111.81M |
| Operating Cash Flow | 111.36M | 50.46M | (31.81M) | 24.23M | (9.72M) |
| Capital Expenditures | (23.51M) | (34.1M) | (26.8M) | (19.23M) | (19.95M) |
| Acquisitions (Net) | 0 | (25.72M) | (69.5M) | 0 | 0 |
| Purchases of Investments | (733.39M) | (467.65M) | (535.66M) | (264.31M) | (85.66M) |
| Sales of Investments | 570.02M | 569.49M | 546.22M | 306.46M | 257.07M |
| Other Investing Activities | (9.33M) | (8.86M) | 0 | (46.4M) | (78.59M) |
| Investing Cash Flow | (186.88M) | 33.17M | (85.74M) | (23.48M) | 72.88M |
| Debt Repayment | 0 | 0 | 0 | 44.91M | (40.76M) |
| Common Stock Issued | 0 | 17.55M | 0 | (6.73M) | (2.61M) |
| Common Stock Repurchased | 0 | 0 | 0 | (30M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 51.93M | (675K) | 4.11M | 183K | 0 |
| Financing Cash Flow | 51.93M | 16.88M | 4.11M | 8.37M | (43.37M) |
| Effect of Forex Changes | 153K | 827K | (212K) | 1.26M | 1.61M |
| Net Change in Cash | (23.43M) | 101.34M | (113.65M) | 10.37M | 21.4M |
| Free Cash Flow | 87.85M | 16.37M | (58.61M) | 4.99M | (29.67M) |
Tandem Diabetes Care, Inc.
NASDAQ:TNDM
Intrinsic Alpha fair value
Locked
Current Price
$17.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.